We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
Hemspan states that it designs bio-based building systems and products for construction by combining modern methods, technology and hemp to produce net-zero carbon solutions. The company argues that every time an average house is built, the CO2 emitted by the manufacture, transport and assembly of the materials used is around 50 to 60 tonnes. Hemspan says that one hectare of UK-grown industrial hemp can absorb 11 tonnes of CO2 each year with regeneratively farmed hemp capable of sequestering a further 6 tonnes per hectare of CO2 into the soil each year. Hemspan intends to activate significant demand for hemp farming in the UK and develop processing technologies to reduce reliance on imports and enable large scale manufacturing of bio-based cladding and insulation products that spin out of R&D programmes. It asserts that the global industrial hemp market is expected to grow at 25% CAGR reaching US$ 27 billion by 2028. It aims to be a contender in this segment. 
days to go: Expired investment: £200,000
Alert Technology Limited is set to transform health and safety best practice for asbestos management by introducing ALERT - a new generation of real-time asbestos monitoring. With the large potential market, Alert will give market priority to the sectors who have demonstrated the greatest need. ALERT is the only solution to the global problem that impacts 30+ industry sectors. Till now, they have successfully launched the ALERT PRO 1000-the first model in the range and won an industry award in the asbestos category. With the investment, they will strengthen their team by recruiting a new Sales Director, Technical Sales Support, Technicians and Service Engineers to boost the in-house team, expand distribution, drive sales, scale-up assembly and service customers.

Pitch Rated

74%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £10,000
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £70,900
We are a property Market Place matching Buyers and Sellers, Landlords and Tenants without the use of estate agents. The online portal will dramatically reduce the fees that sellers and landlords pay agents to find buyers and tenants for their properties
days to go: Expired investment: Withheld
Lost At Sea (LAS) is an independent lifestyle beer brand that targets adventurers. The company has sold 26,000+ beers since 2019, with its products stocked in 50+ outlets. LAS claims that its new online shop has a 21.82% conversion rate and an engaged community of over 30,000 people. It also points out that since its first brew in 2019, it has seen substantial growth in demand, and as a result, provides kegs to its flagship stockist to ensure they have a constant flow of stock. The company has made over £1,000 Royal National Lifeboat Institution (RNLI) donations to date. They intend to use the investment to build a community of like-minded beer lovers, launch a flagship bar in Abersoch, North Wales to advocate local produce and sustainability, create a scalable bar concept for future expansion in other coastal towns, and hire personnel to drive product innovation and sales.
days to go: Expired investment: £82,351
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph